Cardiovascular Medicine and Haematology articles for Germany

Time frame: 1 June 2025 - 30 May 2026

View topic

Count: 248

Article ‘Count’ for Cardiovascular Medicine and Haematology.

Journal Count Share
2 0.99
Toward a ToxAtlas of Carbon-Based Nanomaterials: Single-Cell RNA Sequencing Reveals Initiating Cell Circuits in Pulmonary Inflammation 0.86
Targeted Knockdown of Epithelial Estrogen Receptor α to Mitigate Ferroptosis and Epithelial–Mesenchymal Transition in Eosinophilic Asthma 0.13
3 2.44
An efficient framework to assess the predictive value of 4D ultrasound-based wall motion indices for abdominal aortic aneurysm rupture risk stratification 0.75
Recovery of coronary artery distensibility after two and four years in vivo degradation of a resorbable magnesium-based scaffold 0.69
The porcine abattoir blood model — Bridging the gap between human and porcine blood for in-vitro testing 1.00
1 0.05
An Extravascular Synergistic Cocktail Therapeutic Strategy Based on Lanifibranor Loaded Self-Healing Bioelastomer for Abdominal Aortic Aneurysms 0.05
16 1.84
Astegolimab for COPD With Frequent Exacerbations: Pooled Analysis of the ALIENTO and ARNASA Trials 0.06
Dupilumab in COPD: A Pooled Analysis of Emergency Department Visits, Hospital Admissions, and Systemic Corticosteroid Use 0.08
Nerandomilast in idiopathic pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-IPF trial 0.08
Idiopathic Pulmonary Fibrosis Risk Loci in East Asian Populations Mirror those of European Populations 0.02
Phase 2b trial of inhaled imatinib for treatment of pulmonary arterial hypertension 0.08
The Long-term Pneumonia Mortality Index. An International Multicenter Derivation and Validation Study for Patients with Community-Acquired Pneumonia 0.33
International validation of electronic nose technology as diagnostic tool for fibrotic interstitial lung diseases 0.18
Effect of Dupilumab on Mucus Burden in Patients with Moderate-to-Severe Asthma: The VESTIGE Trial. 0.06
Upper Airway Microbiome, Mucociliary Function, and Clinical Outcomes in Bronchiectasis: Data from the EMBARC-BRIDGE Study. 0.04
Randomized Sham Controlled Trial of Targeted Lung Denervation in Patients with COPD (AIRFLOW-3). 0.05
Inflammation and Obesity Correlate in Pulmonary Hypertension but Associate with Diverging Outcomes. 0.03
Impact of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Tolerance and Abnormal Glucose Metabolism: A Phase 3b, Open-Label Clinical Trial. 0.06
Hemodynamics and Phosphodiesterase-5 Inhibitor Treatment Associated with Survival in ILD-PH: A PVRI GoDeep Meta-Registry Analysis. 0.49
Lipid Ratios for Diagnosis and Prognosis of Pulmonary Hypertension 0.10
Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children ≥6 Years with Cystic Fibrosis and at Least One F508del Allele: A 192-Week, Phase 3, Open-Label Extension Study. 0.06
<atl>Consistent Safety and Efficacy of Sotatercept for Pulmonary Arterial Hypertension in iBMPR2/i Mutation Carriers and Noncarriers: A Planned Analysis of a Phase II, Double-Blind, Placebo-controlled Clinical Trial (PULSAR)</atl> 0.11
1 0.13
A QCM-Based Biosensor to Detect HIT-like Antibodies: Differentiating KKO from RTO via FcγRIIA Interactions 0.13
2 0.98
Two-year efficacy and safety of anti-interleukin-5/receptor therapy for eosinophilic granulomatosis with polyangiitis 0.05
Effects of different B-cell-depleting strategies on the lymphatic tissue 0.93
2 0.13
Impact of Evolving Treatment Patterns on Interstitial Lung Disease Progression in Systemic Sclerosis Using the European Scleroderma Trials and Research Database 0.06
The Effect of Benralizumab and Mepolizumab on Use of Oral Glucocorticoids in Patients with Eosinophilic Granulomatosis with Polyangiitis 0.07
5 2.95
Clonal hematopoiesis and lymphoma-associated mutations in hematopoietic progenitors in B-cell non-Hodgkin lymphoma 1.00
The landscape and evolution of clonal hematopoiesis in chronic lymphocytic leukemia 0.82
A novel cause of type 1 Von Willebrand Disease: impaired exocytosis of Weibel-Palade bodies due to biallelic MADD variants 0.08
A non-coding mutation within the NOTCH1 gene initiates oncogenic NOTCH signaling via wild type NICD stabilization in CLL 1.00
The MURANO study: final analysis and retreatment/crossover substudy results of VenR for patients with relapsed/refractory CLL 0.05
1 0.25
Dominant rhabdomyolysis linked to a recurrent ATP2A2 variant reducing SERCA2 function in muscle 0.25
1 0.18
<atl>Open surgery iversus/i branched endovascular repair of the aortic arch in residual dissections after type A surgical repair</atl> 0.18
1 0.10
Axes of biological variation in diffuse large B cell lymphoma 0.10
2 0.94
Deletion of Mfn2 in endothelial cells triggers a mitohormetic response that improves systemic metabolism and healthspan in mice 0.08
Cystine import and oxidative catabolism fuel vascular growth and repair via nutrient-responsive histone acetylation 0.86
10 3.42
Three-Year Outcomes of Proximal Hypoglossal Nerve Stimulation in OSA 0.06
Admission Eosinophil Count Is Associated With Hospital Resource Use in Community-Acquired Pneumonia 1.00
The Impact of Disease Severity and Symptoms on Anxiety and Depression in Individuals With Idiopathic Pulmonary Fibrosis 0.29
Management and Long-Term Outcomes of Persistent Tachypnea of Infancy/Neuroendocrine Cell Hyperplasia of Infancy: A European Multicenter Retrospective Study 0.23
Incidence of new comorbidities after steroid use in patients with sarcoidosis: an international cross-sectional survey 0.14
Chronic thromboembolic pulmonary disease with exercise pulmonary hypertension – A non-invasive model to predict exercise hemodynamics 0.02
Differential effects of antifibrotic treatment on outcome prediction via serial CRPM levels in IPF 0.60
An inventory of clinical sarcoidosis status in the United States 0.04
Beryllium Lymphocyte Proliferation Test: Differential Diagnosis of Sarcoidosis and Chronic Beryllium Disease 1.00
Exercise Doppler Echocardiography of the right heart and pulmonary circulation in patients with cardiovascular risk factors: Observations from the RIGHT Heart International NETwork (RIGHT-NET) 0.04
17 4.50
Integrative Molecular Analyses of Inflammatory and Autoimmune Signals in Cardiac Sarcoidosis 0.04
Evolocumab in Patients With Prior Percutaneous Coronary Intervention and No Prior Myocardial Infarction: Results From the VESALIUS-CV Trial 0.04
Phone-Based Intervention Under Nurse Guidance for Control of Hypertension After Stroke: A Randomized Multicenter Phase 3 Trial in Ghana. 0.01
Mir147 Limits the Contribution of Non-Foamy Macrophages to Atherosclerosis. 0.96
PAM-VT 2 Study: Long-Term Scar Evolution and Ablation Lesion Assessment by Late Gadolinium Enhancement Cardiac Magnetic Resonance After Ventricular Tachycardia Ablation. 0.04
Natural History of Patients With Histologically Proven Acute Eosinophilic Myocarditis. 0.14
Leveraging a Genetic Proxy to Investigate the Effects of Lifelong Cardiac Sodium Channel Blockade. 0.20
Quantitative Identification of High-Risk Tricuspid Regurgitation by Cardiac Magnetic Resonance. 0.11
Incidence, Risk Factors, and Outcomes in Stressor-Associated Atrial Fibrillation: Insights from the VITAL-AF Trial 0.03
Nuclear eNOS Interacts With and S-Nitrosates ADAR1 to Modulate Type I Interferon Signaling and Endothelial Function. 0.98
Heart Stress and Blood Pressure Management in Older Adults: Post Hoc Analysis of the ASPREE Trial. 0.03
Bailout Intracranial Angioplasty or Stenting After Thrombectomy for Acute Large Vessel Occlusion: 1-Year Outcomes of ANGEL-REBOOT. 0.02
Hypercontractility and Oxidative Stress Drive Creatine Kinase Dysfunction in Hypertrophic Cardiomyopathy. 0.60
Dapagliflozin in Patients Hospitalized for Heart Failure: Primary Results of the DAPA ACT HF-TIMI 68 Randomized Clinical Trial and Meta-Analysis of Sodium-Glucose Cotransporter-2 Inhibitors in Patients Hospitalized for Heart Failure. 0.01
Peri-interventional Anesthesia Strategies for Transcatheter Aortic Valve Implantation: A Multicenter, Randomized, Controlled, Non-inferiority Trial. 1.00
Prognostic Role of Myocarditis-Like Episodes and Their Treatment in Patients With Pathogenic Desmoplakin Variants. 0.03
Transcatheter Aortic Valve Replacement With Balloon- Versus Self-Expandable Bioprostheses for the Treatment of Bicuspid Aortic Valve Stenosis 0.28
3 1.63
Metabolic Factors Modulating the Connection Between Diabetes and Pulmonary Alterations. 0.86
Familial Hypercholesterolemia in Pediatric Patients With Type 1 Diabetes: Double Challenge for Diagnosis and Treatment. 0.70
Cardiovascular Outcomes and Efficacy of the PCSK9 Inhibitor Evolocumab in Individuals With Type 1 Diabetes: Insights From the FOURIER Trial. 0.06
1 0.74
Towards real life exposure: nasal epithelial cell stimulation with pollen particle aerosols 0.74
28 8.31
Cancer and heart failure: prevalence, incidence, and prognosis in Scotland 0.07
PCSK9 inhibitor treatment and outcomes in patients with atherosclerotic cardiovascular disease but without prior ischaemic events: an observational study 0.10
Cardiac resynchronization therapy with or without atrioventricular node ablation in atrial fibrillation: the CAAN-AF trial 0.05
Stroke and systemic embolism following atrial fibrillation ablation: the EMBOL-AF Global Registry 0.23
Sex differences in cardiovascular–kidney–metabolic syndrome: the FINE-HEART pooled analysis 0.12
SLC4A3-related short QT syndrome assessed in human induced pluripotent stem cell-derived cardiomyocytes: mechanisms of ventricular arrhythmia and sudden cardiac death 0.62
Pelacarsen and lipoprotein(a) apheresis in secondary prevention: the Lp(a)FRONTIERS APHERESIS trial 0.67
Soluble ST2 drives fulminant myocarditis progression via the IGF2R–YY1 mitochondrial axis 0.10
Computed tomography-guided vs conventional catheter ablation for ventricular tachycardia: the InEurHeart trial 0.20
Macrophage-specific circular RNA circHIPK2, inflammation, and fibrosis after myocardial infarction 1.00
Pulsed field vs radiofrequency ablation for paroxysmal atrial fibrillation: the BEAT PAROX-AF trial 0.24
Major arrhythmias in non-dilated left ventricular cardiomyopathy: a novel prediction score 0.05
The junctional protein associated with coronary artery disease predicts adverse cardiovascular events in patients with acute coronary syndromes at high residual risk 0.06
Mitral transcatheter edge-to-edge repair and outcomes according to baseline health status: the RESHAPE-HF2 trial 0.36
Catecholaminergic polymorphic ventricular tachycardia mediated by ryanodine receptor 2: a validated risk stratification 0.02
Sex-specific cardiac ageing and sympathetic compensation: a translational study 0.18
Endotypes of angina with non-obstructive coronary arteries: a prospective multicentre study 0.18
Early outcomes of children with univentricular circulation undergoing Fontan surgery: the EuroFontan registry 0.07
Fulminant myocarditis: outcome predictors in an international cohort study 0.78
Cytosolic calcium handling signature: integration with clinical predictors enhances prediction of post-operative atrial fibrillation 0.91
Sex-specific outcomes after transcatheter or surgical treatment of aortic valve stenosis: the DEDICATE-DZHK6 trial 0.97
Atrial fibrillation and atherosclerosis cause different vascular brain lesions on magnetic resonance imaging 0.05
Aspirin, cardiovascular events, and major bleeding in older adults: extended follow-up of the ASPREE trial 0.02
Coronary function testing vs angiography alone to guide treatment of angina with non-obstructive coronary arteries: the ILIAS ANOCA trial 0.12
Titin-related familial dilated cardiomyopathy: factors associated with disease onset 0.02
Long-term trials of colchicine for secondary prevention of vascular events: a meta-analysis 0.11
Long QT syndrome in children and adolescents: risk factors and outcomes in a large German cohort 1.00
Immune checkpoint inhibitor-associated myocarditis: a novel risk score 0.04
1 0.13
A brain-to-lung signal from GABAergic neurons to ADRB2+ interstitial macrophages promotes pulmonary inflammatory responses 0.13
1 0.33
Receptor-Mediated and Hydrolytic Denitrosylation of Dinitrosyl Iron Complexes to Yield Amorphous FexOy and Its Photoinduced Transformation into Crystalline Fe@FexOy Nanoparticles 0.33
1 0.98
Impact of preoperative body mass index on postoperative outcomes in infective endocarditis: a multicenter analysis of 4801 consecutive patients 0.98
1 0.40
Early Invasive or Conservative Strategies for Older Patients With Acute Coronary Syndromes 0.40
8 2.09
Predictors of Long-Term Outcomes in Hypertrophic Cardiomyopathy 0.04
Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes 0.00
SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria 0.05
Effects of Sodium Glucose Cotransporter 2 Inhibitors by Diabetes Status and Level of Albuminuria 0.06
Individualized Perioperative Blood Pressure Management in Patients Undergoing Major Abdominal Surgery 0.92
Long-Term Continuous Monitoring of New-Onset Atrial Fibrillation After Coronary Artery Bypass Grafting 0.88
Respiratory Gas Shifts to Delay Asphyxiation in Critical Avalanche Burial 0.09
Individualized Prediction of Platelet Transfusion Outcomes in Preterm Infants With Severe Thrombocytopenia 0.05
3 1.81
Rhinovirus Infection Promotes Suppression of Sphingosine and Enhanced Bacterial Infection in Cystic Fibrosis Airways 0.83
Inflamed endothelial cells express S1PR1 inhibitor CD69 to induce vascular leak 0.09
A dual role of fibroblast–epithelial crosstalk in acute and chronic lung injury 0.88
8 3.06
Lipoprotein(a)-Associated Proteomic Signature Predicts Cardiovascular Disease in Young Adults 0.07
Fibrosis-memory is mediated by IL-3–producing T cells and drives progression of fibrosis 1.00
Carriage of rare APOB variants predisposes to severe steatotic liver disease and hepatocellular carcinoma 0.03
Clonal hematopoiesis activates pro-calcific pathways in macrophages and promotes aortic valve stenosis 0.57
CDKL1 variants affecting ciliary formation predispose to thoracic aortic aneurysm and dissection 1.00
Platelet-specific SLFN14 deletion causes macrothrombocytopenia and platelet dysfunction through dysregulated megakaryocyte and platelet gene expression 0.17
Wilms tumor 1 impairs apoptotic clearance of fibroblasts in distal fibrotic lung lesions 0.07
PIEZO1 mediates periostin+ myofibroblast activation and pulmonary fibrosis in mice 0.15
3 0.25
Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. 0.07
Remission Assessment by Circulating Tumor DNA in Large B-cell Lymphoma. 0.14
Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321). 0.04
7 2.51
When NCX switches sides: Experimental and computational insights into Ca2+ regulation in the heart 0.86
Females exhibit greater cardiac volume reductions with expiratory muscle loading during submaximal exercise compared to males 0.29
Myosin motor dynamics and cardiac function: Insights from in vivo small-angle X-ray scattering and pressure–volume analysis 0.18
Mechanistic insights into sex differences in atrial electrophysiology and arrhythmia vulnerability through sex‐specific computational models 0.05
Blebbistatin reduces calcium buffering in cardiomyocytes: Consequences for cellular electrophysiology 1.00
Computational modelling of the pro‐ and antiarrhythmic effects of atrial high rate‐dependent trafficking of small‐conductance calcium‐activated potassium channels 0.08
Computational modelling of cardiac fibroblast signalling reveals a key role for Ca2+ in driving atrial fibrillation‐associated fibrosis 0.06
5 2.27
Ten-year outcomes of valve-replacing versus valve-sparing aortic root replacement in Marfan syndrome patients: An observational multicenter study 0.08
Aortic remodeling and pulmonary autograft performance over 2 decades after the Ross procedure in the pediatric and young adult population 1.00
Microinvasive, off-pump, transventricular neochordae implantation in recurrent mitral valve regurgitation after open heart surgical repair 0.07
Second cross-clamp in less invasive mitral valve repair for degenerative mitral regurgitation: Predictors and outcomes 0.16
Early extraction versus conservative management in patients with non-infected cardiac implantable electronic devices undergoing cardiac surgery for left-sided infective endocarditis: Insights from the multicentric CAMPAIGN Registry 0.96
22 3.29
Effectiveness and Safety of Early Rhythm Control in Patients With Atrial Fibrillation and Chronic Kidney Disease 0.59
ECG Signatures and Long-Term Ischemic Stroke Risk A Deep Learning Analysis of 200,000 Patients 0.04
Quality of Life After Percutaneous Coronary Intervention or Medical Therapy for Chronic Total Coronary Occlusions: EUROCTO and DECISION-CTO Meta-Analysis 0.12
Comparison of Sirolimus- vs Paclitaxel-Coated Balloon Angioplasty for Femoropopliteal Artery Disease: The SIRONA Randomized Noninferiority Trial 0.77
Pulsed Field Ablation vs Standard Radiofrequency Ablation for Typical Atrial Flutter: ADVANTAGE AF Trial Substudy 0.14
Pulsed-Field Ablation to Enhance the Durability of Pulmonary Vein Isolation and Treat Paroxysmal Atrial Fibrillation 0.21
Pulsed Field Ablation Using a Novel Biphasic Catheter vs Thermal Ablation for Paroxysmal Atrial Fibrillation InsightPFA Trial 0.02
Aficamten in Obstructive Hypertrophic Cardiomyopathy: A Multi-Domain, Patient-Level Analysis of the MAPLE-HCM Trial 0.03
One-year outcomes of novel balloon-expandable versus contemporary transcatheter heart valves in severe aortic stenosis: the LANDMARK trial 0.10
Proactive Management and Treatment of Aortic Stenosis: An International Expert Perspective 0.09
Sex-Specific Microaxial Flow Pump Use and Outcomes in Infarct-Related Cardiogenic Shock in the DanGer Shock Trial 0.46
Incremental Value of Cardiac Myosin-Binding Protein C for the Early Diagnosis of Acute Myocardial Infarction 0.03
Danicamtiv, a selective agonist of cardiac myosin, for dilated cardiomyopathy: A Phase 2 open-label trial 0.07
Pathogenic Cardiomyopathy-Associated Gene Variants and Prognosis in Atrial Fibrillation Results in 18,000 Clinical Trial Participants 0.17
Personalized or Standard Duration of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention: PARTHENOPE Randomized Trial 0.03
Echocardiographic Changes With Mavacamten in Nonobstructive Hypertrophic Cardiomyopathy Exploratory Insights From the ODYSSEY-HCM Trial 0.05
A Polygenic Risk Score to Predict Incident Heart Failure Across the Spectrum of Cardiovascular Risk 0.02
Anthropometric Measures, Cardiovascular Outcomes, and Treatment Effects of Finerenone in Cardiovascular-Kidney-Metabolic Disease: Pooled Participant-Level Analysis of Three Global Trials 0.13
Effect of Vericiguat on Worsening Heart Failure in Compensated Outpatients with HFrEF: Insights from VICTOR 0.07
Effects of Mavacamten on Cardiac Biomarkers in Nonobstructive Hypertrophic Cardiomyopathy Insights From the ODYSSEY-HCM Trial 0.04
Effect of Aficamten Compared with Metoprolol on Echocardiographic Measures in Symptomatic Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCM 0.03
Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension Results of an International Multicenter Prospective Registry 0.07
2 0.27
Acute eGFR Changes and Their Mediation of Albuminuria Reduction with Empagliflozin and Finerenone. 0.12
Baseline Kidney Function, Albuminuria, and Urine Albumin-Creatinine Ratio Reduction with Finerenone, Empagliflozin, or Both: Post Hoc Analyses of CONFIDENCE Trial. 0.15
1 0.04
Proteogenomic and observational evidence implicate ANGPTL4 as a potential therapeutic target for colorectal cancer prevention 0.04
1 0.03
Imidazole propionate is a driver and therapeutic target in atherosclerosis 0.03
24 11.06
A deep learning ECG model for identification and localization of occlusion myocardial infarction 0.08
Persistence of alveolar fibroblast-derived ADAMTS4+ cells in a preclinical model of delayed pulmonary fibrosis resolution 0.92
Glycaemic variability underlies myocyte dysfunction and myocardial injury risk in diabetes 0.08
Precision cardiovascular risk prediction in type 1 diabetes: An IMI2 SOPHIA analysis 0.17
NK cells promote cardiac cell death and regulate myelopoiesis in myocardial infarction 0.25
Single-cell genomics highlight MYC-associated metabolic activation and altered cell interactions in T-prolymphocytic leukemia progression 0.61
A gut microbiome-kidney-heart axis predictive of future cardiovascular diseases 0.08
Activation of IRF3 in cardiomyocytes impairs mitochondrial oxidative function through PGC-1α inhibition and drives heart failure 0.91
Depression of tryptophan may contribute to adverse effects of naproxen 0.04
Single cell spatial transcriptomics integration deciphers the morphological heterogeneity of atherosclerotic carotid arteries 0.66
NLRP3-induced systemic inflammation controls the development of JAK2V617F mutant myeloproliferative neoplasms 0.94
CFTR modulator therapy drives microbiome restructuring through improved host physiology in cystic fibrosis: the IMMProveCF phase IV trial 0.93
A cross-study transcriptional patient map of heart failure defines conserved multicellular coordination in cardiac remodeling 0.74
Multi-cohort high-dimensional proteomics reveals early risk markers for lymphoid cancer subtypes 0.02
Adipocyte FMO3-derived TMAO induces WAT dysfunction and metabolic disorders by promoting inflammasome activation in ageing 0.07
Integrated single-cell atlas of human atherosclerotic plaques 1.00
Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with high tumor burden: phase II trial 0.05
Aging affects reprogramming of pulmonary capillary endothelial cells after lung injury in male mice 0.10
Inhibition of epithelial cell YAP-TEAD/LOX signaling attenuates pulmonary fibrosis in preclinical models 0.33
In vivo measurement of an Apelin gradient with a genetically encoded APLNR conformation biosensor 1.00
Metabolic reprogramming of the neovascular niche promotes regenerative angiogenesis in proliferative retinopathy 0.02
AI-Based screening for thoracic aortic aneurysms in routine breast MRI 1.00
Sex-specific lipidomic signatures in aortic valve disease reflect differential fibro-calcific progression 1.00
Myocardial mitochondrial antiviral signaling protein promotes heart Ischemia-reperfusion injury via RIG-I signaling in mice 0.08
11 0.97
The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial 0.36
Predicting referral need for febrile children in low-resource community settings in South and Southeast Asia 0.01
Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial 0.05
In vivo base editing gene therapy for heterozygous familial hypercholesterolemia: a phase 1 trial 0.06
Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial 0.04
An oral, liver-restricted LXR inverse agonist for dyslipidemia: preclinical development and phase 1 trial 0.06
Fractional flow reserve-guided percutaneous coronary intervention versus medical therapy for stable coronary artery disease: long-term results of the FAME 2 trial 0.07
Global, regional, and national burden of chronic respiratory diseases and impact of the COVID-19 pandemic, 1990–2023: a Global Burden of Disease study 0.01
Multi-omic definition of metabolic obesity through adipose tissue–microbiome interactions 0.14
Cardiovascular outcomes of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice 0.17
Comparison of dual therapies for hypertension treatment in India: a randomized clinical trial 0.01
4 2.20
Beta arrestin 1 is a key regulator of pulmonary vascular tone 1.00
Spatial control of myosin regulatory light chain phosphorylation modulates cardiac thick filament mechanosensing 0.20
RHOA controls oncogenic B cell receptor signaling in aggressive lymphoma 0.90
Bone morphogenetic protein-9 controls pulmonary vascular growth and remodeling 0.10
4 0.42
Targeting modulated vascular smooth muscle cells in atherosclerosis via FAP-directed immunotherapy 0.15
Deep-learning analysis of 3D microarchitectural remodeling in hypertrophic cardiomyopathy 0.04
Preventing hypocontractility-induced fibroblast expansion alleviates dilated cardiomyopathy 0.09
Resistin-like molecule γ attacks cardiomyocyte membranes and promotes ventricular tachycardia 0.15
5 2.74
EZH2 inhibition via GSK-126 mitigates EndMT and atherosclerosis in diabetes: A translational epigenetic approach 0.05
The pleuroparenchymal fibroelastosis atlas reveals aberrant cell states and their zonation as an alternate roadmap to lung fibrosis 0.54
A beneficial environment promotes immune resilience through epigenetic regulation 1.00
CLL to Richter syndrome: Integrating network strategies with experiments elucidating disease drivers and personalized therapies 1.00
Transcriptome fingerprinting of aberrant fibroblast activation unlocks effective therapeutics to tackle cardiac fibrosis 0.15
4 1.98
CCR5 and CD74 are potential therapeutic targets for necroinflammation in preclinical cholesterol crystal embolism 0.33
Natural killer cell immunotherapy reverses lung fibrosis by eliminating senescent fibroblasts 0.78
Extracellular BRICK1 drives heart repair after myocardial infarction in mice 0.81
Dysregulated alveolar type 2 epithelial cell proteostasis promotes fibrogenic macrophage migration inhibitory factor–CD74 signaling 0.06
2 0.09
Impact of shifting blood donation policy from gift to honour model: staggered difference-in-differences analysis in China 0.06
P2Y12 inhibitor or aspirin after percutaneous coronary intervention: individual patient data meta-analysis of randomised clinical trials 0.03
2 1.93
Plakoglobin transmits tension across VE-cadherin for vascular leak formation and leukocyte diapedesis 1.00
TRPML1 suppresses pulmonary fibrosis by limiting collagen and elastin deposition 0.93
3 0.20
Avapritinib achieves long-term disease control with favorable safety in patients with indolent systemic mastocytosis over 3 years 0.11
Nasal gene expression shows a distinct signature in T2-high asthma but not in T2-low disease 0.04
Genetic characterization of preschool wheeze phenotypes 0.06
9 1.05
Prediction of mortality, bleeding, and ischaemic events in patients with cancer and acute coronary syndrome: a model development and validation study 0.07
Abluminus DES+ sirolimus-eluting stent versus everolimus-eluting stent in patients with diabetes and coronary artery disease (ABILITY Diabetes Global): results from a multicentre, randomised controlled trial 0.13
Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial 0.09
Transcatheter aortic valve implantation with the Trilogy valve for symptomatic native aortic regurgitation (ALIGN-AR): a pivotal, multicentre, single-arm, investigational device exemption study 0.08
Sultiame once per day in obstructive sleep apnoea (FLOW): a multicentre, randomised, double-blind, placebo-controlled, dose-finding, phase 2 trial 0.55
Clopidogrel versus aspirin for secondary prevention of coronary artery disease: a systematic review and individual patient data meta-analysis 0.02
Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial 0.03
Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials 0.03
Collaboration on the optimal timing of anticoagulation after ischaemic stroke and atrial fibrillation: a systematic review and prospective individual participant data meta-analysis of randomised controlled trials (CATALYST) 0.03
1 0.23
Effects of empagliflozin on conventional and exploratory acute and chronic kidney outcomes: an individual participant-level meta-analysis 0.23
1 0.06
Prevalence of non-communicable disease risk factors and chronic conditions among middle-aged and older adults in extreme poverty: a nationally representative cross-sectional study in India 0.06
15 2.98
Phase 3 Trials of Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis 0.05
Pulsed Field Ablation as Initial Therapy for Persistent Atrial Fibrillation 0.03
Sirolimus-Coated Balloon Angioplasty for Infrainguinal Artery Disease 0.03
Mavacamten in Adolescents with Obstructive Hypertrophic Cardiomyopathy 0.05
Angiography-Based Physiology to Guide Coronary Revascularization 0.08
Left Atrial Appendage Closure or Medical Therapy in Atrial Fibrillation 0.99
Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis 0.06
Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism 0.02
Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia 0.37
Antithrombotic Therapy after Successful Catheter Ablation for Atrial Fibrillation 0.16
Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis 0.14
Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy 0.03
Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy 0.08
Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction 0.88
Phase 3 Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis 0.04
3 1.89
Transcriptomic signatures of IPF in ALI-cultured airway cells and their therapeutic implications 0.84
Clinical, molecular and microbial characterisation of the eosinophilic endotype of bronchiectasis: data from the EMBARC-BRIDGE study 0.05
Sex differences in outcome after endoscopic lung volume reduction (ELVR) in patients with emphysema: a retrospective analysis of the German Lung Emphysema Registry (LER e.V.) 1.00

Numerical information only (in the tables above) is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International.